FR2618073B1 - Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation - Google Patents

Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation

Info

Publication number
FR2618073B1
FR2618073B1 FR8710048A FR8710048A FR2618073B1 FR 2618073 B1 FR2618073 B1 FR 2618073B1 FR 8710048 A FR8710048 A FR 8710048A FR 8710048 A FR8710048 A FR 8710048A FR 2618073 B1 FR2618073 B1 FR 2618073B1
Authority
FR
France
Prior art keywords
salbutamol
hydrophilic matrix
active principle
preparation
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR8710048A
Other languages
English (en)
French (fr)
Other versions
FR2618073A1 (fr
Inventor
Michel Sournac
Joel Bougaret
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pierre Fabre Medicament SA
Original Assignee
Pierre Fabre Medicament SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pierre Fabre Medicament SA filed Critical Pierre Fabre Medicament SA
Priority to FR8710048A priority Critical patent/FR2618073B1/fr
Priority to CA000571875A priority patent/CA1330041C/fr
Priority to ES198888401846T priority patent/ES2039285T3/es
Priority to AT88401846T priority patent/ATE73324T1/de
Priority to JP63176872A priority patent/JPS6434914A/ja
Priority to EP88401846A priority patent/EP0299877B1/fr
Priority to DE8888401846T priority patent/DE3869002D1/de
Publication of FR2618073A1 publication Critical patent/FR2618073A1/fr
Application granted granted Critical
Publication of FR2618073B1 publication Critical patent/FR2618073B1/fr
Priority to US07/774,724 priority patent/US5132116A/en
Priority to GR920401095T priority patent/GR3004752T3/el
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FR8710048A 1987-07-16 1987-07-16 Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation Expired - Fee Related FR2618073B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR8710048A FR2618073B1 (fr) 1987-07-16 1987-07-16 Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
CA000571875A CA1330041C (fr) 1987-07-16 1988-07-13 Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
AT88401846T ATE73324T1 (de) 1987-07-16 1988-07-15 Salbutamoltabletten mit hydrophiler matrix und verfahren zu ihrer herstellung.
JP63176872A JPS6434914A (en) 1987-07-16 1988-07-15 Tablet and manufacture
ES198888401846T ES2039285T3 (es) 1987-07-16 1988-07-15 Comprimidos del tipo con matriz hidrofila a base de salbutamol y su procedimiento de preparacion.
EP88401846A EP0299877B1 (fr) 1987-07-16 1988-07-15 Comprimés de type à matrice hydrophile à base de salbutamol et leur procédé de préparation
DE8888401846T DE3869002D1 (de) 1987-07-16 1988-07-15 Salbutamoltabletten mit hydrophiler matrix und verfahren zu ihrer herstellung.
US07/774,724 US5132116A (en) 1987-07-16 1991-10-08 Tablets of the hydrophilic matrix type based on salbutamol and a process for their preparation
GR920401095T GR3004752T3 (enExample) 1987-07-16 1992-05-28

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8710048A FR2618073B1 (fr) 1987-07-16 1987-07-16 Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation

Publications (2)

Publication Number Publication Date
FR2618073A1 FR2618073A1 (fr) 1989-01-20
FR2618073B1 true FR2618073B1 (fr) 1990-09-07

Family

ID=9353198

Family Applications (1)

Application Number Title Priority Date Filing Date
FR8710048A Expired - Fee Related FR2618073B1 (fr) 1987-07-16 1987-07-16 Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation

Country Status (9)

Country Link
US (1) US5132116A (enExample)
EP (1) EP0299877B1 (enExample)
JP (1) JPS6434914A (enExample)
AT (1) ATE73324T1 (enExample)
CA (1) CA1330041C (enExample)
DE (1) DE3869002D1 (enExample)
ES (1) ES2039285T3 (enExample)
FR (1) FR2618073B1 (enExample)
GR (1) GR3004752T3 (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2666506A1 (fr) * 1990-09-07 1992-03-13 Pf Medicament Comprime a liberation prolongee a base de 5-mononitrate d'isosorbide et son procede de preparation.
US5155383A (en) * 1992-02-03 1992-10-13 Motorola, Inc. Circuit and method of resetting a master/slave flipflop
US5298261A (en) * 1992-04-20 1994-03-29 Oregon Freeze Dry, Inc. Rapidly distintegrating tablet
DE4329794C2 (de) * 1993-09-03 1997-09-18 Gruenenthal Gmbh Tramadolsalz enthaltende Arzneimittel mit verzögerter Wirkstofffreisetzung
US5773025A (en) * 1993-09-09 1998-06-30 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems--amorphous drugs
US6726930B1 (en) 1993-09-09 2004-04-27 Penwest Pharmaceuticals Co. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5455046A (en) * 1993-09-09 1995-10-03 Edward Mendell Co., Inc. Sustained release heterodisperse hydrogel systems for insoluble drugs
US5662933A (en) * 1993-09-09 1997-09-02 Edward Mendell Co., Inc. Controlled release formulation (albuterol)
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
EP0759745A4 (en) * 1994-05-13 1997-11-19 Smithkline Beecham Corp METHOD AND COMPOSITION FOR INCREASING FIXATION OF CALCIUM
US5945125A (en) * 1995-02-28 1999-08-31 Temple University Controlled release tablet
WO1997026865A1 (en) * 1996-01-29 1997-07-31 Edward Mendell Co., Inc. Sustained release excipient
ATE417604T1 (de) 1996-07-08 2009-01-15 Penwest Pharmaceuticals Co Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
US6056977A (en) 1997-10-15 2000-05-02 Edward Mendell Co., Inc. Once-a-day controlled release sulfonylurea formulation
IT1297461B1 (it) * 1997-10-29 1999-12-17 Ciocca Maurizio Preparazione di compresse a rilascio controllato a base di complessi tra carragenano e farmaci basici solubili
BR0009437A (pt) * 1999-03-31 2002-01-15 Janssen Pharmaceutica Nv Amido pré-gelatinizado em uma formulação de liberação controlada
CA2352211C (en) * 1999-09-30 2009-03-24 Edward Mendell Co., Inc. Sustained release matrix systems for highly soluble drugs
JP2005515966A (ja) * 2001-07-06 2005-06-02 エンドー ファーマシューティカルズ， インコーポレイティド 鎮痛薬としての使用のための６−ヒドロキシ−オキシモルホンの経口投与
TWI338583B (en) * 2004-05-20 2011-03-11 Otsuka Pharma Co Ltd Solid pharmaceutical formulation
PT1931346E (pt) * 2005-09-09 2012-08-14 Angelini Labopharm Llc Composição de trazodona para administração uma vez por dia
BRPI0615860B8 (pt) * 2005-09-09 2021-05-25 Labopharm Barbados Ltd composição farmacêutica de liberação prolongada monolítica sólida
US20070160960A1 (en) * 2005-10-21 2007-07-12 Laser Shot, Inc. System and method for calculating a projectile impact coordinates

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1338235A (en) * 1970-12-15 1973-11-21 May & Baker Ltd Azapurinones
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
FR2525474A1 (fr) * 1982-04-26 1983-10-28 Roussel Uclaf Nouvelle forme pharmaceutique orale de clometacine
FR2535202B1 (fr) * 1982-11-03 1985-08-09 Fabre Sa Pierre Comprimes de theophylline a liberation controlee et leur procede de fabrication
WO1985004100A1 (en) * 1984-03-21 1985-09-26 American Home Products Corporation Sustained release pharmaceutical capsules
GB8514665D0 (en) * 1985-06-11 1985-07-10 Eroceltique Sa Oral pharmaceutical composition
GB8521494D0 (en) * 1985-08-29 1985-10-02 Zyma Sa Controlled release tablet
GB8613689D0 (en) * 1986-06-05 1986-07-09 Euro Celtique Sa Pharmaceutical composition
US4824677A (en) * 1986-12-18 1989-04-25 The Unjohn Company Grooved tablet for fractional dosing of sustained release medication
DE3720757A1 (de) * 1987-06-24 1989-01-05 Bayer Ag Dhp-manteltablette

Also Published As

Publication number Publication date
ATE73324T1 (de) 1992-03-15
FR2618073A1 (fr) 1989-01-20
ES2039285T3 (es) 1993-09-16
GR3004752T3 (enExample) 1993-04-28
US5132116A (en) 1992-07-21
JPS6434914A (en) 1989-02-06
EP0299877A1 (fr) 1989-01-18
EP0299877B1 (fr) 1992-03-11
CA1330041C (fr) 1994-06-07
DE3869002D1 (de) 1992-04-16

Similar Documents

Publication Publication Date Title
FR2618073B1 (fr) Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
Miller et al. The release of PGE2-like activity into aqueous humor after paracentesis and its prevention by aspirin
CA2067228A1 (en) Drug delivery system, method for preparing the same and use thereof
FR2635265B1 (fr) Composition pharmaceutique intraveineuse comprenant de la cyclosporine en tant que principe actif et procede pour sa preparation
Salinsky et al. Effects of oxcarbazepine and phenytoin on the EEG and cognition in healthy volunteers
IE831799L (en) Controlled release naproxen and naproxen sodium tablets.
EP0816413A3 (en) Purified polylactide and pharmaceutical composition thereof
IL65875A0 (en) Capsules containing the active principle of an allergen,and process for their preparation
DE3852145D1 (de) Indolderivate, Verfahren zu deren Herstellung und pharmazeutische Präparate, die diese enthalten.
CA2037569A1 (en) Controlled release formulation
PT90308A (pt) Processo para a preparacao de composicoes farmaceuticas contendo azelastina com libertacao controlada da substancia activa
Arteaga et al. γ‐Vinyl GABA (vigabatrin): relationship between dosage, plasma concentrations, platelet GABA‐transaminase inhibition, and seizure reduction in epileptic children
ATE121936T1 (de) Isosorbide-5-mononitrate enthaltende tablette mit verzögerter abgabe und verfahren zu ihrer herstellung.
Pahwa et al. Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single‐dose study
CA2006184A1 (en) Prolonged release composition based on trimebutine and process for the preparation thereof
IE820810L (en) Pharmaceutical preparations for treatment of diabetes
HUT53891A (en) Nematocide insecticide and acaricide comprising 5-substituted-3-arylisoxazole derivatives as active ingredient and process for producing the active ingredients
Bantz et al. A double-blind evaluation of skin test suppression produced by two doses of terfenadine
Hohl et al. In vitro activity of the new quinolone RO 23-6240 (AM-833) and the new cephalosporins RO 15-8074 and RO 19-5247 (T-2525) against Mycobacterium fortuitum and Mycobacterium chelonae
Diaz et al. Acute cerebral revascularization: part 3. Cerebral blood flow
Virtanen et al. Serum concentration of rifampin after oral administration
GR3018795T3 (en) Emulsion-free emulsion polymers in sustained-release pharmaceutical compositions and their production
Targum et al. The TRH test and thyroid hormone in refractory depression.
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
Vagen et al. An experimental evaluation of the euphoric properties of antiparkinson drugs on healthy subjects.

Legal Events

Date Code Title Description
ST Notification of lapse